Figure 5.

Proposed therapies in HFpEF. The schematic representation depicts the current and future approach towards the therapeutic options of HFpEF. Future approaches can be either pharmacologic or non-pharmacologic. Pharmacologically promising drugs are Statin (lower cholesterol levels), PDEI5 (Inhibitor of Cyclic GMP in blood vessel lining) and NTG (blood vessels relaxation), however, the treatment options for HFpEF are now shifting towards new paradigm in which drugs are mainly anti-anginal. But, in future the focus will be mainly on treatment of comorbidities and precipitating factors. On the other hand, non-pharmacologic options include healthy diet, treatment of comorbidities and skilled persons for early diagnosis. *HFrEF: Heart Failure with Reduced Ejection Fraction; ACE1: Angiotensin Converting Enzymes 1; ARB: Angiotensin II Receptor Blockers; BB: Beta Blockers; HTN: Hypertension; AF: Atrial Fibrillation; MMP-1: Matrix Metalloproteinase-1; EPO alfa: Epoetin alfa.